VNRX — Volitionrx Ltd
AMEX · Healthcare · Medical Devices
$0.37
-$0.02 (-5.89%)
Volitionrx Ltd (VNRX) is a medical devices company listed on AMEX. It is led by Cameron Reynolds MBA, based in 1489 West Warm Springs Road, Henderson, NV, United States, 89014, with about 67 employees. VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.
Latest reported VNRX revenue for 2025-09-30 was $627.3K. Net income was -$5.4M. Revenue was up 54.2% from 2025-06-30 to 2025-09-30. VNRX currently screens at market cap $15.9M.
Use this VNRX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the VNRX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the VNRX SEC filings page. Lician reads the product cache first so this HTML stays unique to Volitionrx Ltd even when a live quote feed is slow.
About Volitionrx Ltd
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.
VNRX Key Statistics
Market Cap
$15.87M
Volume
565,642
Previous Close
$0.39
Day Range
$0.37 – $0.41
P/B Ratio
38.44
EPS
-$0.31
Revenue
$1.23M
Net Income
-$27.26M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+59.1%
Profit Margin
-2209.8%
Employees
67
VNRX Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $1.23M | $775.30K | $306.39K | $90.03K |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$27.26M | -$35.68M | -$30.60M | -$26.99M |
| EPS (Diluted) | -$0.31 | -$0.50 | $0.00 | $0.00 |
Total Assets
$9.40M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$3.26M
Operating Cash Flow
-$25.89M
Free Cash Flow
$0.00
Volitionrx Ltd Company Information
- Founder, CEO, President & Director
- Cameron Reynolds MBA
- Headquarters
- 1489 West Warm Springs Road, Henderson, NV, United States, 89014
- Website
- volition.com
- Phone
- 512 774 8930
- IPO / Founded
- 2007-04-25
- Sector
- Healthcare
- Industry
- Medical Devices